Early Effects of Human Papillomavirus Vaccination in Belgium


Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.


full text not available (yet).

Authors & affiliation: 
Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. a International Centre for Reproductive Health (ICRH), Ghent University, b Department of Obstetrics and Gynaecology, Ghent University Hospital, Ghent, c Sonic Health Care/AML, Antwerp and d Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
Staff Members: 
Published In: 
European Journal of Cancer Prevention 24 (4): 340–342.
Publication date: 
Friday, July 24, 2015